Cutaneous malignant melanoma
Identifieur interne : 002153 ( Istex/Corpus ); précédent : 002152; suivant : 002154Cutaneous malignant melanoma
Auteurs : Stephen J. Hoffman ; Joseph J. Yohn ; David A. Norris ; Christopher M. Smith ; William A. RobinsonSource :
- Current Problems in Dermatology [ 1040-0486 ] ; 1993.
Abstract
Malignant melanoma is the leading cause of death as a result of skin disease in the United States. The incidence of melanoma has increased exponentially during the last two decades, and the disease is now the eighth most common cause of cancer in the United States, with an estimated annual incidence of approximately 13 per 100,000. Melanoma is curable if diagnosed and treated early in its course, but unfortunately, many patients are still diagnosed with invasive melanoma; the 5-year survival rate for those diagnosed with melanoma that has spread to. regional lymph nodes is 50%. Careful physical examination of pigmented lesions and attention to the clinical history guide the physician toward establishing a diagnosis. The early warning signs of melanoma are a change in the size, shape, or color of a lesion and symptoms associated with pigmented lesions, such as pruritus; ulceration and bleeding are generally late findings in primary melanoma. The ABCD guide for diagnosis of melanoma includes Asymmetry of the lesion, Border irregularity with notching, scalloping, or poorly defined margins, Color variegation, and Diameter greater than 6 mm. The diameter of a lesion should not be used to exclude otherwise suspicious lesions because small diameter melanomas are reported.The cause of melanoma is still unknown but is thought to involve exposure to ultraviolet radiation, possibly years before the tumor is apparent. The increase in incidence of malignant melanoma is probably related to many factors, including increased time spent in outdoor recreational activities, changes in employment trends, and clothing that exposes more skin. A familial form of melanoma exists in cases in which afflicted individuals have large numbers of nevi and melanoma is found in one or more first- or second-degree relatives. These individuals have an almost 100% lifetime risk of developing melanoma. For others, common risk factors include a fair skin type, large numbers of moles, and a history of excessive sun exposure, including sunburning, early in life.Treatment of melanoma is directed at surgical excision of the primary tumor. Adequate excision of thin primary melanoma results in an excellent prognosis. Treatment of melanoma that has metastasized regionally is primarily surgical, and treatment of widespread disease primarily includes chemotherapy-based regimens. The prognosis of advanced-stage disease is poor, and several experimental treatment protocols are being evaluated.
Url:
DOI: 10.1016/1040-0486(93)90016-O
Links to Exploration step
ISTEX:49167F87193A44FEB303D78556D60E09DB819893Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Cutaneous malignant melanoma</title><author><name sortKey="Hoffman, Stephen J" sort="Hoffman, Stephen J" uniqKey="Hoffman S" first="Stephen J." last="Hoffman">Stephen J. Hoffman</name><affiliation><mods:affiliation>Fellow Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</mods:affiliation></affiliation></author><author><name sortKey="Yohn, Joseph J" sort="Yohn, Joseph J" uniqKey="Yohn J" first="Joseph J." last="Yohn">Joseph J. Yohn</name><affiliation><mods:affiliation>Assistant Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</mods:affiliation></affiliation></author><author><name sortKey="Norris, David A" sort="Norris, David A" uniqKey="Norris D" first="David A." last="Norris">David A. Norris</name><affiliation><mods:affiliation>Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</mods:affiliation></affiliation></author><author><name sortKey="Smith, Christopher M" sort="Smith, Christopher M" uniqKey="Smith C" first="Christopher M." last="Smith">Christopher M. Smith</name><affiliation><mods:affiliation>University of Colorado Denver, Colorado, USA</mods:affiliation></affiliation></author><author><name sortKey="Robinson, William A" sort="Robinson, William A" uniqKey="Robinson W" first="William A." last="Robinson">William A. Robinson</name><affiliation><mods:affiliation>Professor of Medicine Director of Clinical Oncology University of Colorado Health Sciences Center Denver, Colorado, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:49167F87193A44FEB303D78556D60E09DB819893</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1016/1040-0486(93)90016-O</idno><idno type="url">https://api.istex.fr/document/49167F87193A44FEB303D78556D60E09DB819893/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002153</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002153</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Cutaneous malignant melanoma</title><author><name sortKey="Hoffman, Stephen J" sort="Hoffman, Stephen J" uniqKey="Hoffman S" first="Stephen J." last="Hoffman">Stephen J. Hoffman</name><affiliation><mods:affiliation>Fellow Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</mods:affiliation></affiliation></author><author><name sortKey="Yohn, Joseph J" sort="Yohn, Joseph J" uniqKey="Yohn J" first="Joseph J." last="Yohn">Joseph J. Yohn</name><affiliation><mods:affiliation>Assistant Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</mods:affiliation></affiliation></author><author><name sortKey="Norris, David A" sort="Norris, David A" uniqKey="Norris D" first="David A." last="Norris">David A. Norris</name><affiliation><mods:affiliation>Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</mods:affiliation></affiliation></author><author><name sortKey="Smith, Christopher M" sort="Smith, Christopher M" uniqKey="Smith C" first="Christopher M." last="Smith">Christopher M. Smith</name><affiliation><mods:affiliation>University of Colorado Denver, Colorado, USA</mods:affiliation></affiliation></author><author><name sortKey="Robinson, William A" sort="Robinson, William A" uniqKey="Robinson W" first="William A." last="Robinson">William A. Robinson</name><affiliation><mods:affiliation>Professor of Medicine Director of Clinical Oncology University of Colorado Health Sciences Center Denver, Colorado, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Current Problems in Dermatology</title><title level="j" type="abbrev">YMDM</title><idno type="ISSN">1040-0486</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993">1993</date><biblScope unit="volume">5</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="7">7</biblScope><biblScope unit="page" to="41">41</biblScope></imprint><idno type="ISSN">1040-0486</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1040-0486</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Malignant melanoma is the leading cause of death as a result of skin disease in the United States. The incidence of melanoma has increased exponentially during the last two decades, and the disease is now the eighth most common cause of cancer in the United States, with an estimated annual incidence of approximately 13 per 100,000. Melanoma is curable if diagnosed and treated early in its course, but unfortunately, many patients are still diagnosed with invasive melanoma; the 5-year survival rate for those diagnosed with melanoma that has spread to. regional lymph nodes is 50%. Careful physical examination of pigmented lesions and attention to the clinical history guide the physician toward establishing a diagnosis. The early warning signs of melanoma are a change in the size, shape, or color of a lesion and symptoms associated with pigmented lesions, such as pruritus; ulceration and bleeding are generally late findings in primary melanoma. The ABCD guide for diagnosis of melanoma includes Asymmetry of the lesion, Border irregularity with notching, scalloping, or poorly defined margins, Color variegation, and Diameter greater than 6 mm. The diameter of a lesion should not be used to exclude otherwise suspicious lesions because small diameter melanomas are reported.The cause of melanoma is still unknown but is thought to involve exposure to ultraviolet radiation, possibly years before the tumor is apparent. The increase in incidence of malignant melanoma is probably related to many factors, including increased time spent in outdoor recreational activities, changes in employment trends, and clothing that exposes more skin. A familial form of melanoma exists in cases in which afflicted individuals have large numbers of nevi and melanoma is found in one or more first- or second-degree relatives. These individuals have an almost 100% lifetime risk of developing melanoma. For others, common risk factors include a fair skin type, large numbers of moles, and a history of excessive sun exposure, including sunburning, early in life.Treatment of melanoma is directed at surgical excision of the primary tumor. Adequate excision of thin primary melanoma results in an excellent prognosis. Treatment of melanoma that has metastasized regionally is primarily surgical, and treatment of widespread disease primarily includes chemotherapy-based regimens. The prognosis of advanced-stage disease is poor, and several experimental treatment protocols are being evaluated.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>melanoma</json:string><json:string>malignant</json:string><json:string>metastasis</json:string><json:string>metastatic</json:string><json:string>malignant melanoma</json:string><json:string>cutaneous</json:string><json:string>node</json:string><json:string>nevus</json:string><json:string>melanocyte</json:string><json:string>prognostic</json:string><json:string>dermatol</json:string><json:string>chemotherapy</json:string><json:string>lesion</json:string><json:string>surg</json:string><json:string>bfgf</json:string><json:string>metastatic melanoma</json:string><json:string>receptor</json:string><json:string>cutaneous melanoma</json:string><json:string>oncogene</json:string><json:string>dysplastic</json:string><json:string>dtic</json:string><json:string>melanoma cells</json:string><json:string>excision</json:string><json:string>balch</json:string><json:string>curr</json:string><json:string>acad</json:string><json:string>tamoxifen</json:string><json:string>oncol</json:string><json:string>transfected</json:string><json:string>soong</json:string><json:string>prognostic factors</json:string><json:string>primary lesions</json:string><json:string>metastatic disease</json:string><json:string>primary melanoma</json:string><json:string>surgical margins</json:string><json:string>adjuvant</json:string><json:string>histologic</json:string><json:string>surgical</json:string><json:string>regional lymph nodes</json:string><json:string>mutation</json:string><json:string>lymphocyte</json:string><json:string>fibroblast</json:string><json:string>malignant transformation</json:string><json:string>dermatology</json:string><json:string>tumor thickness</json:string><json:string>interferon</json:string><json:string>tumor cells</json:string><json:string>autologous</json:string><json:string>response rate</json:string><json:string>ultraviolet radiation</json:string><json:string>dysplastic nevi</json:string><json:string>kopf</json:string><json:string>nat1</json:string><json:string>ulceration</json:string><json:string>elnd</json:string><json:string>encoding</json:string><json:string>lymph</json:string><json:string>probl</json:string><json:string>mutant</json:string><json:string>inst</json:string><json:string>dermis</json:string><json:string>subcutaneous</json:string><json:string>primary tumor</json:string><json:string>recombinant</json:string><json:string>melanocytic</json:string><json:string>melanoma patients</json:string><json:string>murine</json:string><json:string>recurrence</json:string><json:string>invasive</json:string><json:string>chromosome</json:string><json:string>subungual</json:string><json:string>physical examination</json:string><json:string>ultraviolet light</json:string><json:string>response rates</json:string><json:string>cisplatin</json:string><json:string>growth factor</json:string><json:string>malignant melanomas</json:string><json:string>immune</json:string><json:string>primary melanomas</json:string><json:string>prognosis</json:string><json:string>regimen</json:string><json:string>rigel</json:string><json:string>nonfamilial</json:string><json:string>lymphatic</json:string><json:string>acad dermatol</json:string><json:string>gene therapy</json:string><json:string>immunotherapy</json:string><json:string>carmustine</json:string><json:string>randomized</json:string><json:string>acidic</json:string><json:string>nodular melanomas</json:string><json:string>autocrine</json:string><json:string>proc</json:string><json:string>resected</json:string><json:string>breslow</json:string><json:string>survival rate</json:string><json:string>nodular</json:string><json:string>median</json:string><json:string>nerve growth factor</json:string><json:string>human melanocytes</json:string><json:string>risk factors</json:string><json:string>growth factors</json:string><json:string>suspicious lesions</json:string><json:string>skin lesions</json:string><json:string>human melanoma</json:string><json:string>benign nevi</json:string><json:string>surgical excision</json:string><json:string>malignancy</json:string><json:string>atypical</json:string><json:string>vaccine</json:string><json:string>benign</json:string><json:string>nodular melanoma</json:string><json:string>large numbers</json:string><json:string>clark level</json:string><json:string>lifetime risk</json:string><json:string>basement membrane</json:string><json:string>lymph nodes</json:string><json:string>brain metastases</json:string><json:string>local recurrence</json:string><json:string>primary lesion</json:string><json:string>multifactorial analysis</json:string><json:string>proc nat1 acad</json:string><json:string>evaluable patients</json:string><json:string>adjuvant therapy</json:string><json:string>endothelial cells</json:string><json:string>nat1 cancer inst</json:string><json:string>atypical nevi</json:string><json:string>soong teds</json:string><json:string>early detection</json:string><json:string>biologic</json:string><json:string>biopsy</json:string><json:string>tumor</json:string><json:string>lippincott</json:string><json:string>pathologic</json:string><json:string>gene encoding</json:string><json:string>tumor initiation</json:string><json:string>killer cells</json:string><json:string>pigment cells</json:string><json:string>growth pattern</json:string><json:string>early diagnosis</json:string><json:string>vertical growth phase</json:string><json:string>clinical suspicion</json:string><json:string>arch surg</json:string><json:string>skin cancer</json:string><json:string>higher incidence</json:string><json:string>oral contraceptives</json:string><json:string>partial responses</json:string><json:string>colorado health center denver</json:string><json:string>familial melanoma</json:string><json:string>survival rates</json:string><json:string>gene expression</json:string><json:string>distant metastases</json:string><json:string>arch dermatol</json:string><json:string>surgical treatment</json:string><json:string>median survival</json:string><json:string>systemic disease</json:string><json:string>nude mice</json:string><json:string>endothelial</json:string><json:string>infusion</json:string><json:string>carcinoma</json:string><json:string>peptide</json:string><json:string>gene</json:string><json:string>tumor volume</json:string><json:string>prognostic indicator</json:string><json:string>nuclear volume</json:string><json:string>biologic therapy</json:string><json:string>combination chemotherapy</json:string><json:string>biologic response modifiers</json:string><json:string>physical findings</json:string><json:string>melanoma growth</json:string><json:string>warning signs</json:string><json:string>systemic spread</json:string><json:string>growth factor receptors</json:string><json:string>immune response</json:string><json:string>unpublished data</json:string><json:string>curr probl dermatol</json:string><json:string>cell lines</json:string><json:string>melanoma tumors</json:string><json:string>irregular borders</json:string><json:string>prognostic index</json:string><json:string>interferon alfa</json:string><json:string>other agents</json:string><json:string>cell proliferation</json:string><json:string>single agent</json:string><json:string>nonulcerated lesions</json:string><json:string>neural crest</json:string><json:string>scalp lesions</json:string><json:string>autologous bone marrow transplantation</json:string><json:string>complete response</json:string><json:string>thin melanomas</json:string><json:string>metastatic melanomas</json:string><json:string>nonfamilial melanoma</json:string><json:string>continuous infusion</json:string><json:string>colorado melanoma clinic</json:string><json:string>local recurrences</json:string><json:string>separate study</json:string><json:string>anatomic location</json:string><json:string>lung metastases</json:string><json:string>recent study</json:string><json:string>multivariate analysis</json:string><json:string>worse prognosis</json:string><json:string>clinical risk factors</json:string><json:string>malignant cells</json:string><json:string>widespread disease</json:string><json:string>soong shaw</json:string><json:string>lower extremity</json:string><json:string>primary site</json:string><json:string>excisional biopsy</json:string><json:string>dermatology university</json:string><json:string>surg oncol</json:string><json:string>metastatic tumors</json:string><json:string>reticular dermis</json:string><json:string>tumor regression</json:string><json:string>research interests</json:string><json:string>progression</json:string><json:string>extremity</json:string></teeft></keywords><author><json:item><name>Stephen J. Hoffman Ph.D., M.D.</name><affiliations><json:string>Fellow Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</json:string></affiliations></json:item><json:item><name>Joseph J. Yohn M.D.</name><affiliations><json:string>Assistant Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</json:string></affiliations></json:item><json:item><name>David A. Norris M.D.</name><affiliations><json:string>Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</json:string></affiliations></json:item><json:item><name>Christopher M. Smith B.A.</name><affiliations><json:string>University of Colorado Denver, Colorado, USA</json:string></affiliations></json:item><json:item><name>William A. Robinson M.D., Ph.D.</name><affiliations><json:string>Professor of Medicine Director of Clinical Oncology University of Colorado Health Sciences Center Denver, Colorado, USA</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Malignant melanoma is the leading cause of death as a result of skin disease in the United States. The incidence of melanoma has increased exponentially during the last two decades, and the disease is now the eighth most common cause of cancer in the United States, with an estimated annual incidence of approximately 13 per 100,000. Melanoma is curable if diagnosed and treated early in its course, but unfortunately, many patients are still diagnosed with invasive melanoma; the 5-year survival rate for those diagnosed with melanoma that has spread to. regional lymph nodes is 50%. Careful physical examination of pigmented lesions and attention to the clinical history guide the physician toward establishing a diagnosis. The early warning signs of melanoma are a change in the size, shape, or color of a lesion and symptoms associated with pigmented lesions, such as pruritus; ulceration and bleeding are generally late findings in primary melanoma. The ABCD guide for diagnosis of melanoma includes Asymmetry of the lesion, Border irregularity with notching, scalloping, or poorly defined margins, Color variegation, and Diameter greater than 6 mm. The diameter of a lesion should not be used to exclude otherwise suspicious lesions because small diameter melanomas are reported.The cause of melanoma is still unknown but is thought to involve exposure to ultraviolet radiation, possibly years before the tumor is apparent. The increase in incidence of malignant melanoma is probably related to many factors, including increased time spent in outdoor recreational activities, changes in employment trends, and clothing that exposes more skin. A familial form of melanoma exists in cases in which afflicted individuals have large numbers of nevi and melanoma is found in one or more first- or second-degree relatives. These individuals have an almost 100% lifetime risk of developing melanoma. For others, common risk factors include a fair skin type, large numbers of moles, and a history of excessive sun exposure, including sunburning, early in life.Treatment of melanoma is directed at surgical excision of the primary tumor. Adequate excision of thin primary melanoma results in an excellent prognosis. Treatment of melanoma that has metastasized regionally is primarily surgical, and treatment of widespread disease primarily includes chemotherapy-based regimens. The prognosis of advanced-stage disease is poor, and several experimental treatment protocols are being evaluated.</abstract><qualityIndicators><score>8.5</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612.28 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>2489</abstractCharCount><pdfWordCount>18181</pdfWordCount><pdfCharCount>144488</pdfCharCount><pdfPageCount>35</pdfPageCount><abstractWordCount>375</abstractWordCount></qualityIndicators><title>Cutaneous malignant melanoma</title><pii><json:string>1040-0486(93)90016-O</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Proc Natl Acad Sci USA</title><language><json:string>unknown</json:string></language><volume>79</volume><pages><first>2018</first><last>2022</last></pages></serie><host><title>Current Problems in Dermatology</title><language><json:string>unknown</json:string></language><publicationDate>1993</publicationDate><issn><json:string>1040-0486</json:string></issn><pii><json:string>S1040-0486(00)X0014-2</json:string></pii><volume>5</volume><issue>1</issue><pages><first>7</first><last>41</last></pages><genre><json:string>journal</json:string></genre></host><categories><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1016/1040-0486(93)90016-O</json:string></doi><id>49167F87193A44FEB303D78556D60E09DB819893</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/49167F87193A44FEB303D78556D60E09DB819893/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/49167F87193A44FEB303D78556D60E09DB819893/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/49167F87193A44FEB303D78556D60E09DB819893/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Cutaneous malignant melanoma</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1993</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Cutaneous malignant melanoma</title><author xml:id="author-0000"><persName><forename type="first">Stephen J.</forename><surname>Hoffman</surname></persName><roleName type="degree">Ph.D., M.D.</roleName><affiliation>Fellow Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Joseph J.</forename><surname>Yohn</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Assistant Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</affiliation></author><author xml:id="author-0002"><persName><forename type="first">David A.</forename><surname>Norris</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Christopher M.</forename><surname>Smith</surname></persName><roleName type="degree">B.A.</roleName><affiliation>University of Colorado Denver, Colorado, USA</affiliation></author><author xml:id="author-0004"><persName><forename type="first">William A.</forename><surname>Robinson</surname></persName><roleName type="degree">M.D., Ph.D.</roleName><affiliation>Professor of Medicine Director of Clinical Oncology University of Colorado Health Sciences Center Denver, Colorado, USA</affiliation></author><idno type="istex">49167F87193A44FEB303D78556D60E09DB819893</idno><idno type="DOI">10.1016/1040-0486(93)90016-O</idno><idno type="PII">1040-0486(93)90016-O</idno></analytic><monogr><title level="j">Current Problems in Dermatology</title><title level="j" type="abbrev">YMDM</title><idno type="pISSN">1040-0486</idno><idno type="PII">S1040-0486(00)X0014-2</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993"></date><biblScope unit="volume">5</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="7">7</biblScope><biblScope unit="page" to="41">41</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Malignant melanoma is the leading cause of death as a result of skin disease in the United States. The incidence of melanoma has increased exponentially during the last two decades, and the disease is now the eighth most common cause of cancer in the United States, with an estimated annual incidence of approximately 13 per 100,000. Melanoma is curable if diagnosed and treated early in its course, but unfortunately, many patients are still diagnosed with invasive melanoma; the 5-year survival rate for those diagnosed with melanoma that has spread to. regional lymph nodes is 50%. Careful physical examination of pigmented lesions and attention to the clinical history guide the physician toward establishing a diagnosis. The early warning signs of melanoma are a change in the size, shape, or color of a lesion and symptoms associated with pigmented lesions, such as pruritus; ulceration and bleeding are generally late findings in primary melanoma. The ABCD guide for diagnosis of melanoma includes Asymmetry of the lesion, Border irregularity with notching, scalloping, or poorly defined margins, Color variegation, and Diameter greater than 6 mm. The diameter of a lesion should not be used to exclude otherwise suspicious lesions because small diameter melanomas are reported.The cause of melanoma is still unknown but is thought to involve exposure to ultraviolet radiation, possibly years before the tumor is apparent. The increase in incidence of malignant melanoma is probably related to many factors, including increased time spent in outdoor recreational activities, changes in employment trends, and clothing that exposes more skin. A familial form of melanoma exists in cases in which afflicted individuals have large numbers of nevi and melanoma is found in one or more first- or second-degree relatives. These individuals have an almost 100% lifetime risk of developing melanoma. For others, common risk factors include a fair skin type, large numbers of moles, and a history of excessive sun exposure, including sunburning, early in life.Treatment of melanoma is directed at surgical excision of the primary tumor. Adequate excision of thin primary melanoma results in an excellent prognosis. Treatment of melanoma that has metastasized regionally is primarily surgical, and treatment of widespread disease primarily includes chemotherapy-based regimens. The prognosis of advanced-stage disease is poor, and several experimental treatment protocols are being evaluated.</p></abstract></profileDesc><revisionDesc><change when="1993">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/49167F87193A44FEB303D78556D60E09DB819893/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>YMDM</jid><aid>9390016O</aid><ce:pii>1040-0486(93)90016-O</ce:pii><ce:doi>10.1016/1040-0486(93)90016-O</ce:doi><ce:copyright type="unknown" year="1993"></ce:copyright></item-info><head><ce:title>Cutaneous malignant melanoma</ce:title><ce:author-group><ce:author><ce:given-name>Stephen J.</ce:given-name><ce:surname>Hoffman</ce:surname><ce:degrees>Ph.D., M.D.</ce:degrees></ce:author><ce:affiliation><ce:textfn>Fellow Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</ce:textfn></ce:affiliation></ce:author-group><ce:author-group><ce:author><ce:given-name>Joseph J.</ce:given-name><ce:surname>Yohn</ce:surname><ce:degrees>M.D.</ce:degrees></ce:author><ce:affiliation><ce:textfn>Assistant Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</ce:textfn></ce:affiliation></ce:author-group><ce:author-group><ce:author><ce:given-name>David A.</ce:given-name><ce:surname>Norris</ce:surname><ce:degrees>M.D.</ce:degrees></ce:author><ce:affiliation><ce:textfn>Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</ce:textfn></ce:affiliation></ce:author-group><ce:author-group><ce:author><ce:given-name>Christopher M.</ce:given-name><ce:surname>Smith</ce:surname><ce:degrees>B.A.</ce:degrees></ce:author><ce:affiliation><ce:textfn>University of Colorado Denver, Colorado, USA</ce:textfn></ce:affiliation></ce:author-group><ce:author-group><ce:author><ce:given-name>William A.</ce:given-name><ce:surname>Robinson</ce:surname><ce:degrees>M.D., Ph.D.</ce:degrees></ce:author><ce:affiliation><ce:textfn>Professor of Medicine Director of Clinical Oncology University of Colorado Health Sciences Center Denver, Colorado, USA</ce:textfn></ce:affiliation></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Malignant melanoma is the leading cause of death as a result of skin disease in the United States. The incidence of melanoma has increased exponentially during the last two decades, and the disease is now the eighth most common cause of cancer in the United States, with an estimated annual incidence of approximately 13 per 100,000. Melanoma is curable if diagnosed and treated early in its course, but unfortunately, many patients are still diagnosed with invasive melanoma; the 5-year survival rate for those diagnosed with melanoma that has spread to. regional lymph nodes is 50%. Careful physical examination of pigmented lesions and attention to the clinical history guide the physician toward establishing a diagnosis. The early warning signs of melanoma are a change in the size, shape, or color of a lesion and symptoms associated with pigmented lesions, such as pruritus; ulceration and bleeding are generally late findings in primary melanoma. The ABCD guide for diagnosis of melanoma includes <ce:italic>A</ce:italic>symmetry of the lesion, <ce:italic>B</ce:italic>order irregularity with notching, scalloping, or poorly defined margins, <ce:italic>C</ce:italic>olor variegation, and <ce:italic>D</ce:italic>iameter greater than 6 mm. The diameter of a lesion should not be used to exclude otherwise suspicious lesions because small diameter melanomas are reported.</ce:simple-para><ce:simple-para>The cause of melanoma is still unknown but is thought to involve exposure to ultraviolet radiation, possibly years before the tumor is apparent. The increase in incidence of malignant melanoma is probably related to many factors, including increased time spent in outdoor recreational activities, changes in employment trends, and clothing that exposes more skin. A familial form of melanoma exists in cases in which afflicted individuals have large numbers of nevi and melanoma is found in one or more first- or second-degree relatives. These individuals have an almost 100% lifetime risk of developing melanoma. For others, common risk factors include a fair skin type, large numbers of moles, and a history of excessive sun exposure, including sunburning, early in life.</ce:simple-para><ce:simple-para>Treatment of melanoma is directed at surgical excision of the primary tumor. Adequate excision of thin primary melanoma results in an excellent prognosis. Treatment of melanoma that has metastasized regionally is primarily surgical, and treatment of widespread disease primarily includes chemotherapy-based regimens. The prognosis of advanced-stage disease is poor, and several experimental treatment protocols are being evaluated.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Cutaneous malignant melanoma</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Cutaneous malignant melanoma</title></titleInfo><name type="personal"><namePart type="given">Stephen J.</namePart><namePart type="family">Hoffman</namePart><namePart type="termsOfAddress">Ph.D., M.D.</namePart><affiliation>Fellow Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph J.</namePart><namePart type="family">Yohn</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Assistant Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David A.</namePart><namePart type="family">Norris</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Professor Department of Dermatology University of Colorado Health Sciences Center Denver, Colorado, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher M.</namePart><namePart type="family">Smith</namePart><namePart type="termsOfAddress">B.A.</namePart><affiliation>University of Colorado Denver, Colorado, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William A.</namePart><namePart type="family">Robinson</namePart><namePart type="termsOfAddress">M.D., Ph.D.</namePart><affiliation>Professor of Medicine Director of Clinical Oncology University of Colorado Health Sciences Center Denver, Colorado, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Malignant melanoma is the leading cause of death as a result of skin disease in the United States. The incidence of melanoma has increased exponentially during the last two decades, and the disease is now the eighth most common cause of cancer in the United States, with an estimated annual incidence of approximately 13 per 100,000. Melanoma is curable if diagnosed and treated early in its course, but unfortunately, many patients are still diagnosed with invasive melanoma; the 5-year survival rate for those diagnosed with melanoma that has spread to. regional lymph nodes is 50%. Careful physical examination of pigmented lesions and attention to the clinical history guide the physician toward establishing a diagnosis. The early warning signs of melanoma are a change in the size, shape, or color of a lesion and symptoms associated with pigmented lesions, such as pruritus; ulceration and bleeding are generally late findings in primary melanoma. The ABCD guide for diagnosis of melanoma includes Asymmetry of the lesion, Border irregularity with notching, scalloping, or poorly defined margins, Color variegation, and Diameter greater than 6 mm. The diameter of a lesion should not be used to exclude otherwise suspicious lesions because small diameter melanomas are reported.The cause of melanoma is still unknown but is thought to involve exposure to ultraviolet radiation, possibly years before the tumor is apparent. The increase in incidence of malignant melanoma is probably related to many factors, including increased time spent in outdoor recreational activities, changes in employment trends, and clothing that exposes more skin. A familial form of melanoma exists in cases in which afflicted individuals have large numbers of nevi and melanoma is found in one or more first- or second-degree relatives. These individuals have an almost 100% lifetime risk of developing melanoma. For others, common risk factors include a fair skin type, large numbers of moles, and a history of excessive sun exposure, including sunburning, early in life.Treatment of melanoma is directed at surgical excision of the primary tumor. Adequate excision of thin primary melanoma results in an excellent prognosis. Treatment of melanoma that has metastasized regionally is primarily surgical, and treatment of widespread disease primarily includes chemotherapy-based regimens. The prognosis of advanced-stage disease is poor, and several experimental treatment protocols are being evaluated.</abstract><relatedItem type="host"><titleInfo><title>Current Problems in Dermatology</title></titleInfo><titleInfo type="abbreviated"><title>YMDM</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">199301</dateIssued></originInfo><identifier type="ISSN">1040-0486</identifier><identifier type="PII">S1040-0486(00)X0014-2</identifier><part><date>199301</date><detail type="volume"><number>5</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue pages"><start>1</start><end>41</end></extent><extent unit="pages"><start>7</start><end>41</end></extent></part></relatedItem><identifier type="istex">49167F87193A44FEB303D78556D60E09DB819893</identifier><identifier type="DOI">10.1016/1040-0486(93)90016-O</identifier><identifier type="PII">1040-0486(93)90016-O</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002153 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002153 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:49167F87193A44FEB303D78556D60E09DB819893
|texte= Cutaneous malignant melanoma
}}
| This area was generated with Dilib version V0.6.31. |  |